Moreover, as first-line therapy for locally advanced and metastatic HCC consists of a combination of immunotherapy and anti-neoangiogenic treatment (1), PET/CT with PSMA-radioligands may serve as a valuable tool to predict the results of therapy and assess the response to ongoing treatment. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.